N-001

About Neurocarrus

Neurocarrus is a private, preclinical-stage biotech founded in 1986 and based in Seattle, Washington. The company is advancing a novel, modular protein delivery platform called APOLLO to create therapeutics that precisely target neurons, aiming to treat pain and neurodegeneration without the addiction risk or systemic side effects of current standards of care. Its pipeline includes lead asset N-001 for acute/surgical pain, NL-17 for migraines, and several earlier-stage programs for chronic pain and other indications. The company is currently pre-revenue and appears to be raising capital through a crowdfunding initiative.

Therapeutic Areas